Amicus Therapeutics reported a significant 32% revenue increase in 2024, totaling $528 million, driven primarily by Galafold‘s strong performance. Newly launched POMBILITI and OPFOLDA generated over $70 million, targeting late-onset Pompe disease. The company achieved non-GAAP profitability and improved its financial health,

Exact Sciences delivered over 4.6 million cancer test results in 2025, showcasing significant strides in early detection and personalized treatment. The company achieved an 11% core revenue growth while keeping operating expenses up by only 2%, resulting in a 48% rise in